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Disentangling Parkinson’s disease (PD) and progressive supranuclear palsy (PSP) may be a diagnostic challenge. Cognitive signs
may be useful, but existing screens are often insuﬃciently sensitive or unsuitable for assessing people with motor disorders. We
investigated whether the newly developed ECAS, designed to be used with people with even severe motor disability, was sensitive
to the cognitive impairment seen in PD and PSP and able to distinguish between these two disorders. -irty patients with PD, 11
patients with PSP, and 40 healthy controls were assessed using the ECAS, as well as an extensive neuropsychological assessment.
-e ECAS detected cognitive impairment in 30% of the PD patients, all of whom fulﬁlled the diagnostic criteria for mild cognitive
impairment. -e ECAS was also able to detect cognitive impairment in PSP patients, with 81.8% of patients performing in the
impaired range.-e ECAS total score distinguished between the patients with PSP and healthy controls with high sensitivity (91.0)
and speciﬁcity (86.8). Importantly, the ECAS was also able to distinguish between the two syndromes, with the measures of verbal
ﬂuency oﬀering high sensitivity (82.0) and speciﬁcity (80.0). In sum, the ECAS is a quick, simple, and inexpensive test that can be
used to support the diﬀerential diagnosis of PSP.
1. Introduction
It has now been over 50 years since progressive supranuclear
palsy (PSP) was ﬁrst described as a progressive neurological
disorder with motor, ocular, and cognitive features [1].
Clinically, it remains diﬃcult to distinguish from Parkin-
son’s disease (PD) [2, 3], particularly in the early stages [4].
Even when using agreed criteria, the accuracy of diagnosis is
not 100% [5]. As it has a signiﬁcantly worse prognosis than
PD, with a more rapid progression [6], early detection is
crucial for enabling access to appropriate interventions and
support, as well as identifying patients suitable for clinical
trials. In the absence of any disease-speciﬁc biomarkers,
there is a need for a quick, simple, and inexpensive test that
can be used for the diﬀerential diagnosis of PSP.
Both PSP and PD are characterised by extrapyramidal
syndromes, each of which can comprise symptoms of
bradykinesia, rigidity, and/or postural instability [7]. Both
disorders can feature eye movement abnormalities, and
although the presence of the supranuclear vertical gaze palsy
in PSP is diagnostically helpful, it is not universal [8, 9] and
may be absent until quite late in the disease [10]. Although
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both disorders are thought to feature some similar cognitive
signs, there is evidence to suggest that the speciﬁc cognitive
proﬁle may be a useful distinguishing feature [11].
Early cognitive impairment is a feature of PSP, which
may precede the motor or ocular signs [12]. -e proﬁle is
mainly that of executive dysfunction [13] and cognitive
slowing [14], with markedly reduced verbal ﬂuency [15, 16].
Deﬁcits in other domains, including memory [17], language
[18–20], visuospatial [16, 18], and social cognition [21–23],
have also been reported.
In contrast, early stages of PD are characterised by only
mild deﬁcits in executive functions [24–27], but with illness
progression, there is evolution from a mild cognitive im-
pairment (MCI) to dementia, with greater involvement of
posterior-based visual functions [28–30].
Existing screens of cognitive functioning can be criti-
cised for being insuﬃciently sensitive to the cognitive proﬁle
of both PD and PSP. For example, the most widely used
cognitive screen, the MMSE [31], has no measure of verbal
ﬂuency. Both the MMSE and the Addenbrooke’s Cognitive
Examination [32] have inadequate assessment of executive
function. -eir ensuing ceiling eﬀects give them a low de-
tection rate for cognitive impairment in Parkinsonian
syndromes [33–35]. -e Frontal Assessment Battery [36]
does assess verbal ﬂuency and executive function but has no
measure of memory, language, or visuospatial function.
Similarly, the Dementia Rating Scale (DRS) [37] has no
measure of language or visuospatial function. -is reliance
upon the executive functions reduces its ability to dis-
criminate PSP from PD [38] or frontotemporal syndromes
[39]. -e DRS also has a lengthy administration time and
requires specialised testing materials, impractical for routine
bedside use. -e Montreal Cognitive Assessment [40] does
have a measure of verbal ﬂuency but does not accommodate
for physical disability. Indeed, none of the existing assess-
ments were designed speciﬁcally for people with movement
disorders, such as Parkinsonian syndromes. Tasks involving
speaking, writing, or drawing can be inﬂuenced by motor
symptoms such as tremor, rigidity, bradykinesia, apraxia, or
dysarthria; thus, a genuine cognitive impairment might be
sometimes diﬃcult to distinguish from motor dysfunction
and performance decrements exaggerated by physical
disability.
-e ECAS [41] was recently developed as a brief as-
sessment for the identiﬁcation of cognitive and behavioural
changes in disorders characterised by prominent motor
symptoms, such as amyotrophic lateral sclerosis (ALS). It
was developed to be used with patients with even severe
physical disability and thus may be suitable for detecting
cognitive impairment in all motor disorders. Many of the
subtests can be performed either orally or manually, with
some measures corrected for motor speed, reducing the
impact that physical disability may have upon performance
on cognitive tests [42]. It also allows the clinician to track
cognitive impairment throughout the disease course, crucial
for any longitudinal studies.
-e ECAS has been standardised using a sample of
healthy controls, providing normative data for clinical use
[41]. It has also been validated against other screening tools
[43, 44] and extensive neuropsychological assessment [45]. It
is available in English [41], German [46], Swiss German [46],
Italian [44], and Chinese [47]. However, it remains untested
whether the ECAS is also sensitive to the cognitive im-
pairment observed in other progressive movement disor-
ders. -us, the aims of the present study were to determine
ﬁrstly whether the ECAS is sensitive to the cognitive im-
pairment seen in PD and PSP and secondly whether it is able
to distinguish between these disorders, in order to support
the diﬀerential diagnosis of PSP.
2. Methods
2.1. Participants. All patients were recruited from the Na-
tional Hospital for Neurology and Neurosurgery, Queen
Square, London. PSP patients (9 males and 2 females) were
diagnosed using the NINDS-SPSP criteria [48] and had
a mean illness duration of 3.73 years (range 1–11 years). PD
patients (24 males and 6 females) fulﬁlled the Queen Square
Brain Bank criteria for PD and had a mean illness duration
of 5.67 years (range 0–14 years). All patients with PD-MCI
were identiﬁed using the Movement Disorder Society Task
Force guidelines [49], in which impairment (<2 SD) is
present on at least two tests of cognitive functioning, either
within or across diﬀerent cognitive domains.
-e healthy controls were those reported by Niven et al.
[45]. -ey (26 males and 14 females) were recruited through
the PsychologyDepartment of theUniversity of Edinburgh. No
participant had signiﬁcant neurological or psychiatric history.
-e research was done in accordance with the Decla-
ration of Helsinki and approved by the NRES Committee
London-Queen Square and the University of Edinburgh’s
Department of Psychology Ethics Committee.
2.2. Measures. -e ECAS is a 15–20-minute screen that
includes assessment of the following domains: (1) ﬂuency
(free: words beginning with “S” and ﬁxed: words beginning
with “T” but with only four letters); (2) executive functions,
separate from verbal ﬂuency (Reverse Digit Span, Alterna-
tion, Inhibitory Sentence Completion, and Social Cogni-
tion); (3) language (Naming, Comprehension, and Spelling);
(4) memory (Immediate Recall, Delayed Percentage Re-
tention, and Delayed Recognition); and (5) visuospatial (Dot
Counting, Cube Counting, and Number Location). Verbal
ﬂuency measures take into account the slowing of motor
responses, by generating a verbal ﬂuency index corrected for
motor speed. Previously published ECAS normative data
[41] were used to classify the abnormality of performance on
each domain and calculate the total score out of a maximum
of 136 (lower score indicating worse performance), with any
scores <2 SD considered to be impaired.
Extensive neuropsychological testing was administered to
assess the same domains (ﬂuency, executive functions, lan-
guage, memory, and visuospatial; Table 1).Moodwas assessed
using the Hospital Anxiety and Depression Scale [50], and
patients were also assessed using the Apathy Scale [51].
Scores for the neuropsychological assessments were
compared with published normative data. For each measure,
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patients were judged to be impaired if scores were ≤2 SD. In
the case where multiple measures were used, performance
was classiﬁed as impaired when ≤2 SD on one of the two or
two of the three measures was used.
2.3. StatisticalAnalyses. Data were analysed using SPSS v.19.
Between-group comparisons were made using analyses of
variance, and Pearson’s and Spearman’s correlations were
used to detail the relationships between measures. Receiver
operating characteristic (ROC) curve analyses were used to
determine the relative sensitivity and speciﬁcity of the ECAS
for the two patient groups.
3. Results
3.1. Demographics. Demographic details are given in Table 2.
-ere were no signiﬁcant group diﬀerences in age or edu-
cation, and patients did not diﬀer in symptom duration.-ere
were signiﬁcant group eﬀects found for both HADS Anxiety
(F (2, 75)� 13.04; p< 0.001) and Depression (F (2, 77)�
19.03; p< 0.001), with post hoc analysis revealing that pa-
tients had signiﬁcantly higher burden of symptoms than
healthy controls but no signiﬁcant group diﬀerence between
patient groups. -ere was no signiﬁcant group diﬀerence in
apathy scores between patient groups.
3.2. Performance on the ECAS. -ere was a signiﬁcant eﬀect
of diagnosis on ECAS performance (Table 3). PSP patients
had signiﬁcantly lower total scores than PD patients and
healthy controls, and PD patients had signiﬁcantly lower
total scores than healthy controls (all p< 0.017). -ere was
a signiﬁcant eﬀect of diagnosis on all domains, except
visuospatial. PSP patients performed worse than PD patients
and healthy controls on ﬂuency, language, executive func-
tion, and memory (all p< 0.017). PD patients performed
worse than healthy controls on executive function only
(p< 0.017).
When compared to published normative data, 81.8%
(n � 9) of the PSP patients and 30.0% of the PD patients
(n � 9) were impaired on the ECAS. PSP patients demon-
strated most frequent impairments in ﬂuency, language, and
memory (each n � 7; 63.6%) and then executive function
(n � 6; 54.5%) and visuospatial (n � 3; 27.3%). PD patients
demonstrated most frequent impairments in language
(n � 9; 30.0%), executive function and memory (each n � 8;
26.7%), and then ﬂuency and visuospatial (each n � 5;
16.7%). -ere were no signiﬁcant correlations between
duration of symptoms and ECAS scores in either patient
groups.
In order to investigate the speciﬁc nature of the
impairment in both patient groups, individual domains
were further investigated. In ﬂuency, post hoc compar-
isons revealed a signiﬁcant eﬀect of diagnosis on both free
ﬂuency (F (2, 23.16) � 15.19; p< 0.017) and ﬁxed ﬂuency
(F (2, 21.63) � 8.30; p< 0.017), with PSP patients per-
forming worse than PD patients and healthy controls (all
p< 0.017), but with no signiﬁcant diﬀerences between PD
patients and healthy controls. In language, there was
a signiﬁcant group eﬀect on spelling (F (2, 76) � 10.58;
p< 0.017), with PSP patients performing worse than PD
Table 1: Neuropsychological assessment.
Domain Subdomain Measures
Fluency Phonemic verbal ﬂuency index [42] (VFi): words beginning with “P” and “R”
Executive
functions
Inhibition
Hayling Sentence Completion Test [52]: total unconnected errors (converted but not
scaled); latency score (time taken to complete unconnected sentences minus time taken
for connected sentences)
Shifting and
rule detection Brixton Spatial Anticipation Test [52]: total number of errors
Social Reading the Mind in the Eyes–Revised [53]: total number of correct ones
Language Naming Graded Naming Test [54]Spelling Graded Diﬃculty Spelling Test [55]
Memory Adult Memory and Information Processing Battery [56]: immediate story recall;delayed story recall
Visuospatial -e Visual Object and Space Perception Battery [57]: cube analysis; number location
Table 2: Demographics of the participants.
PSP patients PD patients Controls
Mean (SD) Range Mean (SD) Range Mean (SD) Range
Age 66.82 (7.08) 53–77 63.33 (7.89) 50–80 62.70 (10.48) 39–88
Duration of symptoms (years) 3.73 (3.20) 1–11 5.67 (3.47) 0–14 — —
Gender (female) 2 — 6 — 14 —
Education, mean years (SD) 15.27 (4.98) 10–26 14.33 (3.22) 9–23 12.25 (3.39) 9–25
HADS Depression 8.50 (5.50) 1–15 6.77 (4.39) 0–16 2.40 (1.81) 0–6
HADS Anxiety 8.50 (5.79) 2–17 9.17 (4.13) 3–18 4.83 (2.75) 0–11
Apathy 17.67 (12.04) 4–34 15.90 (10.26) 4–42 — —
HADS: Hospital Anxiety and Depression Scale.
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patients and healthy controls (both p< 0.017), but with
no signiﬁcant diﬀerence between PD patients and healthy
controls. In memory, there was a signiﬁcant group eﬀect on
immediate recall (F (2, 24.04)� 11.47; p< 0.017) and re-
tention (F (2, 20.69)� 8.92; p< 0.017), but not recognition.
PSP patients performed signiﬁcantly worse than PD patients
and healthy controls on both of these (both p< 0.017), but
with no signiﬁcant diﬀerence between PD patients and
healthy controls. In executive functions, there were signiﬁcant
group eﬀects on reverse digit span (F (2, 25.96)� 7.60;
p< 0.017), alternation (F (2, 22.92)� 5.66; p< 0.017), and
social cognition (F (2, 20.42)� 9.49; p< 0.017). Both PSP and
PD patients performed signiﬁcantly worse than healthy
controls on reverse digit span and social cognition (all
p< 0.017), but with no signiﬁcant diﬀerences between patient
groups. PSP patients performed signiﬁcantly worse than PD
patients and healthy controls on alternation (p< 0.017), but
with no signiﬁcant diﬀerence between PD patients and
healthy controls.
3.3. Performance on Full Neuropsychological Assessment.
Upon full neuropsychological assessment, there was a sig-
niﬁcant eﬀect of diagnosis on ﬂuency, executive function,
and visuospatial domains (Table 4). Speciﬁcally, there were
signiﬁcant group diﬀerences on both measures of ﬂuency,
with PSP patients performing worse than PD patients and
healthy controls. -ere were no signiﬁcant diﬀerences be-
tween PD patients and healthy controls. In addition, PSP
patients performed worse than healthy controls on the
Table 3: ECAS scores of the participants.
PSP patients PD patients Controls
F (df) p
Mean (SD) Range Mean (SD) Range Mean (SD) Range
Total (max. 136) 85.09 (24.46) 54–126 109.87 (13.52) 78–126 120.61 (7.06) 100–132 17.44 (2, 22.09)a <0.001
Executive function (max. 48) 29.27 (13.27) 9–46 36.93 (6.05) 19–44 42.11 (3.49) 33–48 12.56 (2, 22.22)a <0.001
Language (max. 28) 23.18 (5.06) 15–28 26.67 (2.11) 19–28 27.50 (0.80) 25–28 5.76 (2, 21.01)a <0.001
Fluency (max. 24) 8.18 (8.74) 0–22 18.73 (4.83) 6–24 20.74 (2.39) 12–24 12.37 (2, 21.91)a <0.001
Memory (max. 24) 10.27 (6.90) 0–20 15.67 (4.25) 3–22 18.39 (2.53) 13–23 10.85 (2, 22.76)a <0.001
Visuospatial (max. 12) 11.09 (1.87) 6–12 11.47 (1.04) 8–12 11.87 (0.67) 8–12 2.33 (2, 22.86)a 0.066
aWelch’s adjusted F ratio.
Table 4: Neuropsychological assessment performance of participants.
PSP patients PD patients Healthy controls
F (df) p Post hocMean
(SD) Range
Mean
(SD) Range
Mean
(SD) Range
Fluency
“P” VFi 10.90(6.30) 2.37–19.67
4.13
(2.98) 0.96–14.50
3.68
(1.96) 1.52–9.33 22.65 (2.78) <0.001 PSP<PD
“R” VFi 14.16(13.16) 2.50–41.00
4.12
(2.11) 2.00–9.50
3.65
(1.73) 1.72–9.33 22.37 (2.76) <0.001 PSP<PD
Executive
function
Hayling: B–A time 69.14(86.55) 5–251
33.00
(28.04) −3 to 126 34.88(28.96) −5 to 121 2.88 (2.73) 0.06
Hayling: errors 6.57(5.56) 0–14
5.17
(5.89) 0–29
8.75
(9.17) 0–32 1.80 (2.73) 0.17
Brixton 38.43(3.21) 35–43
34.54
(9.71) 16–50
35.08
(8.23) 15–47 0.59 (2.70) 0.56
Reading the Mind
in the Eyes
20.50
(5.43) 14–29
23.93
(5.06) 13–35
26.35
(3.81) 17–34 5.72 (2.71) <0.01 PSP<HC
Language
Graded Naming
Test
20.64
(5.85) 9–26
23.20
(3.61) 13–29
24.15
(6.64) 14–57 1.71 (2.78) 0.19
Graded Diﬃculty
Spelling Test
19.64
(8.44) 2–29
22.29
(6.01) 7–30
22.53
(4.50) 12–29 1.15 (2.76) 0.32
Memory
Immediate Story
Recall
24.45
(14.20) 0–41
27.04
(9.73) 7–49
Delayed Story
Recall
23.64
(15.54) 0–40
25.46
(9.61) 7–46
Retention 80.16(32.96) 0–111.11
93.92
(14.75) 62.50–136.00
94.49
(12.74) 58.82–12.27 3.12 (2.77) 0.05
Visuospatial
Cube Analysis 8.91(1.58) 6–10
8.83
(1.62) 5–10
9.63
(0.87) 5–10 23.61 (2.78) <0.05 PSP<HC
Number Location 8.45(2.46) 2–10
9.20
(1.00) 7–10
9.43
(0.71) 7–10 2.90 (2.78) 0.06
VFi: Verbal Fluency Index.
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Reading the Mind in the Eyes Test and Cube Analysis, but
with no signiﬁcant diﬀerences between PSP and PD patients,
or between PD patients and healthy controls.
When scores on each of the neuropsychological assess-
ments were compared with published normative data, there
was a signiﬁcant group diﬀerence in incidence of impairment
in one domain only: ﬂuency (χ2 (1)� 7.61; p< 0.001). Nine of
the 11 PSP patients (81.8%) were classiﬁed as impaired on at
least one measure of verbal ﬂuency, in comparison with only
33.3% (n � 10) of the 30 PD patients.
3.4. Diagnostic Accuracy of the ECAS for Cognitive Impair-
ment in PD. Within the PD patients, a total of 17 (56.67%)
met the criteria for PD-MCI. When PD and PD-MCI groups
were compared, there were no signiﬁcant diﬀerences in age,
education, or symptom duration. However, on the ECAS,
the PD-MCI group had signiﬁcantly lower total scores
(t (20.25)� 5.14; p< 0.001) and performed worse on exec-
utive function (t (23.83)� 3.02; p< 0.01), verbal ﬂuency
(t (22.52)� 3.26; p< 0.01), memory (t (28)� 3.09; p< 0.01),
and visuospatial subscales (t (16.00)� 3.11; p< 0.01). On full
neuropsychological assessment, the PD-MCI group also
performed signiﬁcantly worse on the Brixton Test (t (24)�
3.81; p< 0.001), Reading the Mind in the Eyes Test (t (26)�
2.75; p< 0.05), Graded Naming Test (t (28)� 4.32;
p< 0.001), and Cube Analysis (t (20.69)� 2.801; p< 0.05).
ROC curve analysis revealed that the total score of the
ECAS is able to discriminate between PD and PD-MCI with
high sensitivity (88.2%) and 100% speciﬁcity, when using
a threshold score of 112.50/136. -e AUC is 0.93 (SE� 0.06;
p< 0.001). Conﬁdence intervals are 0.81 (lower bound) and
1.00 (upper bound). Indeed, all PD patients who performed
in the impaired range on the ECAS fulﬁlled the diagnostic
criteria for PD-MCI.
3.5. Diagnostic Accuracy of the ECAS for PSP. ROC curve
analysis also revealed that the ECAS is highly speciﬁc
(86.8%) and sensitive (91.0%) when discriminating PSP
patients from healthy controls using a threshold score of
113.50/136. -e AUC is 0.91 (SE� 0.67; p< 0.001). Conﬁ-
dence intervals are 0.79 (lower bound) and 1.00 (upper
bound). All PSP patients who performed in the impaired
range on the ECAS demonstrated impairment upon full
neuropsychological testing, including impairment on at least
one measure of verbal ﬂuency.
3.6. Diagnostic Accuracy of the ECAS for Distinguishing be-
tween PD and PSP. -e second aim of the study was to
determine whether the ECAS is able to distinguish be-
tween PD and PSP, in order to support the early and
accurate diagnosis of PSP. ROC curve analysis showed
that the measure is able to discriminate between PD and
PSP (when comparing all patients, irrespective of cog-
nitive performance), with high speciﬁcity (76.7%) and
sensitivity (72.7%), using a threshold score of 103.50/136
(Figure 1). -e AUC is 0.80 (SE� 0.09; p< 0.01). Conﬁdence
intervals are 0.62 (lower bound) and 0.98 (upper bound). -is
generated three false negatives and seven false positives. -e
false positives were all patients who fulﬁlled the criteria for
PD-MCI.
Within the ECAS, ﬂuency was the best predictor of PSP,
with high speciﬁcity (80.0%) and sensitivity (82.0%) using
a threshold score of 17/24. -e AUC is 0.84 (SE� 0.08;
p< 0.01). Conﬁdence intervals are 0.69 (lower bound) and
1.00 (upper bound). -is generated two false negatives and
six false positives (ﬁve PD-MCI and one PD). -is is in
contrast to when using the raw number of words generated
in the two ﬂuency tasks as a predictor, which has lower
sensitivity (77.8%) and speciﬁcity (79.2%) when using
a threshold score of 17.5.
4. Discussion
Our study has shown that the ECAS is sensitive to the
cognitive impairment seen in PD. We found that 30% of PD
patients were impaired on the ECAS, all of whom also
demonstrated impairments upon full neuropsychological
testing and fulﬁlled the criteria for PD-MCI. Indeed, ROC
curve analyses revealed that the ECAS has excellent sensi-
tivity and complete speciﬁcity for detection of PD-MCI. On
the ECAS, PD patients demonstrated impairments in
a number of domains but performed signiﬁcantly worse than
healthy controls on one domain only: executive function.
PD-MCI patients also demonstrated deﬁcits in language and
visuospatial functioning. -ese ﬁndings conﬁrm the greater
involvement of posterior functions with more advanced
Parkinson’s disease [30] but also suggest that the pattern of
impairment can be fairly heterogeneous, even involving
language. -is is in accordance with the ﬁndings of the MDS
Task Force [49], who also report impairments in a range of
cognitive domains, including language.
Our data also show that the ECAS is sensitive to the
cognitive impairment in PSP. We found that 81.8% of PSP
patients were impaired on both the ECAS and full neuro-
psychological testing, including at least one measure of
1.0
0.8
0.6
0.4
0.2
0.0
Se
ns
iti
vi
ty
0.0 0.2 0.4 0.6 0.8 1.0
1 – specificity
Figure 1: ROC curve depicting sensitivity and speciﬁcity of the
ECAS, when comparing the PD and PSP patients (higher sensitivity
scores indicate lower performance).
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ﬂuency. Again, ROC curve analyses conﬁrmed that the ECAS
total score gave excellent sensitivity and speciﬁcity for
detection of PSP when compared with healthy controls. On
the ECAS, PSP patients demonstrated the expected im-
pairment in ﬂuency, but also executive function, memory,
and language. On extensive neuropsychological testing,
PSP patients demonstrated impairments in ﬂuency as well
as executive function and visuospatial. -e prominence of
ﬂuency and executive impairment on both the ECAS and
full neuropsychological testing is in accordance with
previous descriptions [13, 15, 16, 28], conﬁrming that the
ECAS is sensitive to the typical proﬁle of cognitive im-
pairment in PSP.
Importantly, we also found that the ECAS was able to
distinguish between PD and PSP. ROC curve analysis
revealed that the ECAS total score was sensitive and speciﬁc
to PSP, with verbal ﬂuency being the best discriminator. -e
ECAS was able to identify all PSP cases demonstrating
cognitive impairment upon full testing. -e few false pos-
itives mostly reﬂected PD patients with advanced cognitive
impairment.
-e strikingly reduced verbal ﬂuency found on the ECAS
and full testing conﬁrms this as the cognitive hallmark of
PSP. Importantly, the ECAS revealed this marked deﬁcit
even after accounting for the slowed motor speed. -is
contrasts with impairments in other cognitive domains, such
as memory, which can improve by up to 50% given suﬃcient
extra time [58, 59]. -is impoverished verbal ﬂuency,
alongside the frequent family reports of reduced sponta-
neous speech and conversation initiation, likely reﬂects
a cognitive adynamia beyond that of simple bradyphrenia
but rather a more signiﬁcant impairment in the generation
of a “ﬂuent sequence of novel thought” [19, 60]. -is may
reﬂect a deﬁcit in novel thought generation and/or its ap-
propriate sequencing [61]. Indeed, it has been argued that
the akinesia in motor abilities, reduction of verbal ﬂuency in
cognition, and apathy in behaviour are all diﬀerent mani-
festations of the same underlying disorder [62].
PSP patients also demonstrated impairments in other
domains, which supports the ﬁndings of previous studies. In
accordance with previous reports of poor delayed recall [17],
our PSP patients displayed impaired verbal recall on the
ECAS, with three of the seven PSP patients impaired on both
the ECAS and full testing. Our patients also demonstrated
language impairment, reﬂecting spelling diﬃculties, in ac-
cordance with previous studies [20, 63, 64]. Spelling was
more impaired on the ECAS, perhaps because its spelling
test comprises nouns, verbs, and compounds of low-to-
medium frequency, with a longer mean length. In con-
trast, the spelling test used upon full testing contained
mostly nouns of high-to-low frequency, with a shorter mean
length. Our patients also demonstrated impaired visuo-
spatial function, which supports previous ﬁndings [16, 18].
Nearly a third of PSP patients were impaired on the ECAS,
with all of these also impaired upon full testing.
-e PD and PSP patients both performed poorly on
measures of social cognition. -ese ﬁndings echo previous
reports of impaired performance on tests of theory of mind
and social norms [22, 44, 65–67].
5. Conclusions
-e ECAS captures the core cognitive deﬁcit of reduced
verbal ﬂuency, as well as the wider cognitive proﬁle of PSP.
-is may allow longitudinal testing to track progression as
verbal ﬂuency reaches ﬂoor. It was possible to use the ECAS
with all the patients who took part in this study, despite often
severe motor symptoms, indicating that it would be well
tolerated in those with advanced disease. -is suggests that
the ECAS is suited for bedside use for detecting cognitive
impairment in Parkinsonian syndromes and for dis-
tinguishing diﬀerent cognitive proﬁles within these, in order
to support diﬀerential diagnosis. Full neuropsychological
assessment can then be used to further elucidate the speciﬁc
clinical proﬁle of each patient. Future research should ex-
amine its sensitivity for detecting cognitive impairment in
other progressive movement disorders.
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